Heidi said it has raised US$340 million in new funding, made up of a US$100 million Series C and a US$240 million growth investment from General Catalyst’s Customer Value Fund. The company announced the funding in a post on X.
The Series C carries a US$900 million post-money valuation. Blackbird led the round, joined by Phoenix Court, Point72 Private Investments and Headline. Heidi said its total funding has reached US$436.6 million.
The Customer Value Fund is non-dilutive and takes no equity or warrants in the company. Instead, it fronts sales and marketing costs in exchange for a share of revenue from customers gained through those efforts, SiliconANGLE reported.
Heidi said annual recurring revenue rose from US$1 million to US$50 million in roughly two years, by April 2026. Its AI Care Partner has supported more than 175 million patient visits, up from 73 million at the Series B, the company said. Heidi also reports about 2.8 million patient interactions a week across 110 languages and 190 countries.
Co-founder and CEO Dr. Thomas Kelly said the company is shifting from documenting care toward helping clinicians act on it. Heidi was founded in Melbourne, Australia. Its platform transcribes doctor-patient conversations and can generate clinical notes, referral letters and assessments.
The company previously raised a US$65 million Series B in October 2025 at a US$465 million valuation. Its AI medical scribe competes with Abridge, Nabla, Suki and Microsoft-owned Nuance DAX.
